{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:53Z","timestamp":1787009393865,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0001"],"award-info":[{"award-number":["RD21\/0005\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PMP21\/00\u00a0109"],"award-info":[{"award-number":["PMP21\/00\u00a0109"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is diagnosed when glomerular filtration rate (GFR) falls below 60\u00a0ml\/min\/1.73\u00a0m2 or urinary albumin:creatinine ratio (UACR) reaches \u226530\u00a0mg\/g, as these two thresholds indicate a higher risk of adverse health outcomes, including cardiovascular mortality. CKD is classified as mild, moderate or severe, based on GFR and UACR values, and the latter two classifications convey a high or very high cardiovascular risk, respectively. Additionally, CKD can be diagnosed based on abnormalities detected by histology or imaging. Lupus nephritis (LN) is a cause of CKD. Despite the high cardiovascular mortality of patients with LN, neither albuminuria nor CKD are discussed in the 2019 European League Against Rheumatism (EULAR)\/European Renal Association\u2013European Dialysis and Transplant Association recommendations for the management of LN or the more recent 2022 EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases. Indeed, the proteinuria target values discussed in the recommendations may be present in patients with severe CKD and a very high cardiovascular risk who may benefit from guidance detailed in the 2021 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice. We propose that the recommendations should move from a conceptual framework of LN as an entity separate from CKD to a framework in which LN is considered a cause of CKD and evidence generated from large CKD trials applies unless demonstrated otherwise.<\/jats:p>","DOI":"10.1093\/ndt\/gfad154","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T16:24:16Z","timestamp":1689006256000},"page":"151-158","source":"Crossref","is-referenced-by-count":16,"title":["Chronic kidney disease: the missing concept in the 2019 EULAR\/ERA-EDTA recommendations for lupus nephritis"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-6328","authenticated-orcid":false,"given":"Jorge E","family":"Rojas-Rivera","sequence":"first","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, University Autonoma of Madrid, FRIAT , Madrid , Spain"},{"name":"ISCIII RICORS2040 Kidney Disease Research Network , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-9672","authenticated-orcid":false,"given":"Sevcan A","family":"Bakkaloglu","sequence":"additional","affiliation":[{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"},{"name":"Department of Pediatrics, Division of Pediatric Nephrology and Rheumatology, Gazi University Faculty of Medicine , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3032-245X","authenticated-orcid":false,"given":"Davide","family":"Bolignano","sequence":"additional","affiliation":[{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"},{"name":"Renal Unit, \u201cMagna Graecia\u201d University , Catanzaro , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut","family":"Nistor","sequence":"additional","affiliation":[{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"},{"name":"University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d , Ia\u015fi , Romania"},{"name":"Department of Nephrology \u201cDr C.I. Parhon\u201d Hospital , Ia\u015fi , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis A","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"},{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokratis","family":"Stoumpos","sequence":"additional","affiliation":[{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"},{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow , Glasgow , UK"},{"name":"Renal and Transplant Unit, Queen Elizabeth University Hospital , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario Gennaro","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"},{"name":"Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, University Autonoma of Madrid, FRIAT , Madrid , Spain"},{"name":"ISCIII RICORS2040 Kidney Disease Research Network , Madrid , Spain"},{"name":"European Renal Association-European Renal Best Practice (ERA-ERBP) , Parma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"2023122005162068100_bib1","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023122005162068100_bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ckj\/sfz007","article-title":"Clarifying the concept of chronic kidney disease for non-nephrologists","volume":"12","author":"Perez-Gomez","year":"2019","journal-title":"Clin Kidney J"},{"key":"2023122005162068100_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023122005162068100_bib4","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023122005162068100_bib5","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023122005162068100_bib6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023122005162068100_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","article-title":"A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis","volume":"90","author":"Anders","year":"2016","journal-title":"Kidney Int"},{"key":"2023122005162068100_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/eurheartj\/ehab456","article-title":"Use of chronic kidney disease blind spot to prevent cardiorenal outcomes","volume":"43","author":"Ruilope","year":"2022","journal-title":"Eur Heart J"},{"key":"2023122005162068100_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/gfab167","article-title":"Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease","volume":"38","author":"Ortiz","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005162068100_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023122005162068100_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ckj\/sfaa198","article-title":"SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia","volume":"13","author":"Fernandez-Fernandez","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023122005162068100_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2023122005162068100_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ndt\/gfaa314","article-title":"Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA","volume":"36","author":"ERA-EDTA Council, ERACODA Working Group","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005162068100_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"2023122005162068100_bib15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ckj\/sfz188","article-title":"Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis","volume":"14","author":"Su","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023122005162068100_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"2023122005162068100_bib17","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA"},{"key":"2023122005162068100_bib18","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","article-title":"Survival analysis and causes of mortality in patients with lupus nephritis","volume":"27","author":"Yap","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005162068100_bib19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023122005162068100_bib20","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7\u00a0g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2023122005162068100_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023122005162068100_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023122005162068100_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfab210","article-title":"Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care","volume":"15","author":"Bosi","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023122005162068100_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ckj\/sfab240","article-title":"More on the invisibility of chronic kidney disease\u2026and counting","volume":"15","author":"Carriazo","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023122005162068100_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/gfac254","article-title":"What should European nephrology do with the new CKD-EPI equation?","volume":"38","author":"Gansevoort","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005162068100_bib26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023122005162068100_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2023122005162068100_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023122005162068100_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nefro.2022.10.005","article-title":"Consensus document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis","volume":"43","author":"Rojas-Rivera","year":"2023","journal-title":"Nefrolog\u00eda"},{"key":"2023122005162068100_bib30","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1975\u20132015. A systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023122005162068100_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3899\/jrheum.130005","article-title":"Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment","volume":"41","author":"Touma","year":"2014","journal-title":"J Rheumatol"},{"key":"2023122005162068100_bib32","first-page":"403","article-title":"Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association","volume":"16","author":"Ortiz","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005162068100_bib33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/annrheumdis-2021-221474","article-title":"Call for action in ANCA-associated vasculitis and lupus nephritis promises and challenges of SGLT-2 inhibitors","volume":"81","author":"Saemann","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023122005162068100_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","author":"Fern\u00e1ndez-Fernandez","year":"2023","journal-title":"Clin Kidney J"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad154\/51009646\/gfad154.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/1\/151\/54634049\/gfad154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/1\/151\/54634049\/gfad154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:17:12Z","timestamp":1703031432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/1\/151\/7222916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,11]]},"published-print":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad154","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,7,11]]}}}